BioSpace News Archive

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, May 5, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its first quarter 2021 financial results and to provide a corporate update.

Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa , Chief Executive Officer of Relmada, is scheduled to participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on Tuesday, May 4, 2021

USDA approves the claim that the product is effective for the passive immunization of healthy dogs 13 weeks of age or older against canine parvovirus (CPV) disease Results demonstrated 100% efficacy against the deadly disease, highlighting the potential to address a critical unmet medical need

Catalyst OrthoScience Inc. (Catalyst), a medical device company focused on the upper extremity orthopedics market, is introducing its new Archer™ R1 Reverse Shoulder System as its Archer™ CSR Total Shoulder System continues to gain market share.

Health Passport Subsidiary Medcheks has Launched Next-Generation, Scalable Reopening Tools to Enable Expedited Post-COVID-19 Reopening to Align with Rapidly Evolving Global Mandates

INmune Bio, Inc. (NASDAQ: INMB) (the “Company” or “INmune”), a clinical-stage immunology company focused on developing treatments that harness a patient’s innate immune system to fight disease, today announced that it will host a conference call on Wednesday, May 5, 2021 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2021 and to provide a corporate update.

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its first quarter 2021 financial results after market close on Wednesday, May 5, 2021. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities.

VigiLanz, a clinical surveillance company, today released findings from their third annual hospital patient safety survey

For six years, the Multiple Sclerosis Association of America has been honored to host our annual Improving Lives Benefit in-person, raising funds for the MS community.